UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000006252
Receipt number R000007398
Scientific Title A randomized phase III trial of adjuvant gefitinib versus cisplatin and vinorelbine in completely resected (stage II-III) non-small cell lung cancer (NSCLC) patients with mutated EGFR (investigator-initiated multicenter clinical trial)
Date of disclosure of the study information 2011/09/03
Last modified on 2022/01/06 20:06:31

No. Disposal Last modified on Item of update
1 Insert 2011/08/30 18:51:57
2 Update 2011/09/01 13:02:10 TEL
TEL
3 Update 2011/09/15 10:31:26 Recruitment status
4 Update 2011/10/21 10:44:17 Email
5 Update 2013/04/01 09:48:06 Name of person sending information
Name of person sending information
Email
6 Update 2013/04/04 19:16:54 Email1
7 Update 2014/04/30 15:11:58 Key exclusion criteria
Key exclusion criteria
8 Update 2014/04/30 15:32:28 Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Email
Name of person sending information
Name of person sending information
Email
9 Update 2015/03/30 17:14:29 Email1
10 Update 2016/02/16 16:50:55 Recruitment status
11 Update 2016/03/31 09:26:59 Email1
12 Update 2016/09/02 10:32:36 Name of primary person or sponsor
Organization
13 Update 2019/09/05 10:31:20 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address

Last name of contact person

Last name of contact person
Zip code
Address
Address
Organization
Organization
Address
Address
Tel
Email
14 Update 2019/09/05 10:32:05 Number of participants that the trial has enrolled
15 Update 2019/09/05 10:32:56 Date of IRB
Last follow-up date
16 Update 2020/07/31 10:32:30 Address
Address
17 Update 2021/03/26 13:59:46 Recruitment status
18 Update 2022/01/06 20:06:31 URL releasing protocol
Publication of results
URL related to results and publications
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures